[Rivaroxaban at Non-Valvular Atrial Fibrillation: a Prospective Study and Clinical Practice]

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Nonvalvular atrial fibrillation (AF) poses a significant risk for stroke and systemic thromboembolic complications.
• Effective anticoagulation is crucial for stroke prevention in AF patients.
• Rivaroxaban is an oral anticoagulant used for stroke prevention in nonvalvular AF.

Purpose of the Study:

• To analytically review post-registration clinical studies on rivaroxaban's efficacy and safety in nonvalvular AF.
• To assess rivaroxaban's performance in real-world clinical practice for stroke prevention.
• To evaluate the safety profile, including bleeding risks, associated with rivaroxaban therapy.

Main Methods:

• Review of results from large prospective international observational studies (e.g., XANTUS).
• Analysis of data from a Russian multicenter observational study (Neuro-Xar).
• Examination of retrospective post-marketing studies in the US (e.g., PMSS, REVISIT-US).

Main Results:

• The XANTUS study confirmed rivaroxaban's effectiveness and safety in 6784 real-world, unselected nonvalvular AF patients.
• The Neuro-Xar study demonstrated rivaroxaban's efficacy and safety in secondary stroke prevention in routine practice.
• US post-marketing studies indicated a lower risk of fatal intracranial and gastrointestinal bleeding with rivaroxaban.
• Rivaroxaban therapy was linked to a reduced risk of the combined endpoint of ischemic stroke and intracranial hemorrhage.

Conclusions:

• Rivaroxaban is an effective and safe treatment option for stroke prevention in patients with nonvalvular AF across diverse clinical settings.
• Real-world evidence supports the use of rivaroxaban in routine clinical practice for nonvalvular AF.
• Rivaroxaban therapy is associated with a favorable safety profile, including reduced risks of major bleeding events.